A novel delivery platform for therapeutic peptides |
| |
| Authors: | Sunyoung Park Sang Doo Kim Ha Young Lee Dobeen Hwang Joon Seong Park Yoe-Sik Bae Junho Chung |
| |
| Institution: | 1. Department of Biochemistry and Molecular Biology, Seoul National University School of Medicine, Seoul, Republic of Korea;2. Cancer Research Institute, Seoul National University, Seoul, Republic of Korea;3. Department of Biological Sciences, Sungkyunkwan University, Suwon, Republic of Korea;4. Mitochondria Hub Regulation Center, Dong-A University, Busan, Republic of Korea;5. Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea;6. Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea |
| |
| Abstract: | Although many peptides have therapeutic effects against diverse disease, their short half-lives in vivo hurdle their application as drug candidates. To extend the short elimination half-lives of therapeutic peptides, we developed a novel delivery platform for therapeutic peptides using an anti-hapten antibody and its corresponding hapten. We selected cotinine because it is non-toxic, has a well-studied metabolism, and is physiologically absent. We conjugated WKYMVm-NH2, an anti-sepsis therapeutic peptide, to cotinine and showed that the conjugated peptide in complex with an anti-cotinine antibody has a significantly improved in vivo half-life while retaining its therapeutic efficacy. We suggest that this novel delivery platform for therapeutic peptides will be very useful to develop effective peptide therapeutics. |
| |
| Keywords: | Peptide Therapeutics Stability Delivery Sepsis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
